About Pierre Fabre Laboratories Oncology

Pierre Fabre Laboratories is the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care.   

For over 40 years, Pierre Fabre Laboratories has established itself as an international player in oncology, mastering the entire value chain from R&D to marketing. Its portfolio of oncology specialties covers colorectal, breast, lung and skin cancers, as well as certain hematologic malignancies and precancerous dermatological conditions such as actinic keratosis. In 2024, Pierre Fabre Laboratories’ revenues in oncology came to 520 million euros, 88% of which were generated by international sales, out of a total sales figure of 3.1 billion euros. 

Based in southwest France since its creation, Pierre Fabre Laboratories manufactures more than 90% of its products in France and employs 10,200 people worldwide. In 2024, its R&D budget amounted to 219 million euros, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. There are currently 10 research and development programs underway dedicated to targeted therapies in oncology.

Pierre Fabre Laboratories’ majority shareholder (86%) is an eponymous Foundation, which is recognized by the French government as being a public-interest foundation. Employees constitute the company’s other shareholder. This capital structure guarantees the company’s independence, long-term vision and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world. 

Pierre Fabre Laboratories’ CSR policy has been assessed by AFNOR Certification and has been awarded the “Exemplary” level of its CSR label (ISO 26 000 standard for sustainable development). 

For more information, visit www.pierre-fabre.com, @Laboratoires Pierre Fabre, @Pierre Fabre Oncology